

Tuberculosis profile: Azerbaijan

Population 2019: 10 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	6 000 (4 600-7 600)	60 (46-76)
HIV-positive TB incidence	94 (65-130)	0.94 (0.65-1.3)
MDR/RR-TB incidence**	1 200 (870-1 500)	12 (8.7-15)
HIV-negative TB mortality	590 (550-640)	5.9 (5.4-6.4)
HIV-positive TB mortality	20 (13-28)	0.2 (0.13-0.28)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	11% (10-13)
Previously treated cases	24% (23-26)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	80% (63-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	10% (8-13)

TB case notifications, 2019

Total new and relapse	4 823
- % tested with rapid diagnostics at time of diagnosis	85%
- % with known HIV status	94%
- % pulmonary	81%
- % bacteriologically confirmed ^	75%
- % children aged 0-14 years	5%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	31%
- % men	64%
Total cases notified	6 533

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	71	1.6%
- on antiretroviral therapy	71	100%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	100%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	98%
Laboratory-confirmed cases - MDR/RR-TB ^^	1 031
Patients started on treatment - MDR/RR-TB ^^^	819
Laboratory-confirmed cases - XDR-TB ^^	197
Patients started on treatment - XDR-TB ^^^	186
MDR/RR-TB cases tested for resistance to any fluoroquinolone	704

Treatment success rate and cohort size


	Success	Cohort
New cases registered in 2018	84%	1 751
Previously treated cases registered in 2018	74%	2 433
HIV-positive TB cases registered in 2018		
MDR/RR-TB cases started on second-line treatment in 2017	59%	858
XDR-TB cases started on second-line treatment in 2017	63%	182

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	66%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100-100)



Treatment success rate



Total budget



TB financing

National TB budget, 2020 (US\$ millions)	17
- Funding source, domestic	83%
- Funding source, international	17%
- unfunded	0%

* *Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.*

** *MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin*

^ *Calculated for pulmonary cases only*

^^ *Includes cases with unknown previous TB treatment history*

^^^ *Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed*

Generated 2020-10-21 by the World Health Organization (<https://www.who.int/tb/data/>)